Efficacy and Safety of Lenvatinib Versus Atezolizumab plus Bevacizumab as First-Line Systemic Therapies for Hepatocellular Carcinoma : Experience from a Single UK Centre

Abstract
Atezolizumab plus Bevacizumab (Atezo/Bev) and Lenvatinib (Len) are approved as first-line systemic therapies for unresectable or metastatic hepatocellular carcinoma (HCC) based on the results of benchmark studies which compared them with Sorafenib.1-2 However, there had been no head-to-head comparison between these two therapies in any randomized controlled clinical trials. Three systematic reviews and meta-analyses found no significant difference in the overall survival between patients treated with Atezo/Bev or Len.3-5 However, most had included studies from Asia, and all of them are retrospective cohort studies. Such results may not be generalisable to Western European populations, where the etiology and clinical presentation of HCC differ.
In the United Kingdom, HCC is the 17th most common cancer, but the eighth most common cause of cancer-related death.6 More than 90% of patients with HCC have underlying liver diseases, such as alcoholic cirrhosis, metabolic dysfunction-associated steatotic liver disease (MASLD), or less commonly chronic viral hepatitis (CVH) infection from hepatitis B (HBV) and hepatitis C (HCV). Current 5-year survival of HCC in England is less than 20%, which can be variable in different cancer centres according to their social determinants.
Colchester General Hospital (East Suffolk and North Essex Foundation Trust, ESNEFT) is part of the health care network of East England. All patients with a diagnosis of HCC were reviewed centrally at either the HCC Multidisciplinary Teams of Addenbrooke’s Hospital in Cambridge University or Royal Free Hospital in London, before they were referred back to receive systemic anti-cancer treatment locally. We report our experience of using Atezo/Bev and Len as first-line systemic therapies for HCC in the real world setting.　

Keywords
atezolizumab, bevacizumab, hepatocellular carcioma, lenvatinib

Cite this paper
Eric Ka Chai LEE, Suat Wei LOO, Jennifer Louise COLLINS, Efficacy and Safety of Lenvatinib Versus Atezolizumab plus Bevacizumab as First-Line Systemic Therapies for Hepatocellular Carcinoma : Experience from a Single UK Centre , SCIREA Journal of Clinical Medicine. Volume 11, Issue 1, February 2026 | PP. 23-33. 10.54647/cm321476

References

[ 1 ]	RS Finn, S Qin, M Ikeda, PR Galle, M Ducreux, T-Y Kim, M Kudo, V Breder, P Merle, AO Kaseb, D Li, W Verret, D-Z Xu, S Hernandez, J Liu, C Huang, S Mulla, Y Wang, HY Lim, AX Zhu, A-L Cheng, for the IMbrave 150 Investigators. Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020; 382 (20): 1894-905
[ 2 ]	M Kudo, RS Finn, S Qin, KH Han, K Ikeda, F Piscaglia, A Baron, J-W Park, G Han, J Jassem, JF Blanc, A Vogel, D Komov, TRJ Evans, C Lopez, C Dutcus, M Guo, K Saito, S Kraljevic, T Tamai, M Ren, A-L Cheng. Lenvatinib versus sorafenib in first-line treatment for unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018; 391:1163-73
[ 3 ]	S Du, K Cao, Z Wang, D Lin. Clinical efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib in the treatment of advanced hepatocellular carcinoma. A systematic review and meta-analysis. Medicine 2023;102: 23
[ 4 ]	G Zhu, L Zeng, L Yang, X Zhang, J Tang, Y Pan, B Li, M Chen, T Wu.Is atezolizumab plus bevacizumab as first-line therapy for unresectable hepatocellular carcinoma superior to lenvatinib ? A systemic review and meta-analysis. European Journal of Clinical Pharmacology 2024; 80:1425-1434
[ 5 ]	NPSI Remitha, NPRP Dewi, KWA Kusuma, IGAP Sasmana, IGP Supadmanaba, DA Sindhughosa, IK Mariadi. Efficacy and safety of lenvatinib versus atezolizumab plus bevacizumab in the treatment of unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2025; 26(5) : 1529-1542
[ 6 ]	A Burton, D Tataru, RJ Driver, TG Bird, D Huws, D Wallance, TJS Cross, IA Rowe, G Alexander, A Marshall, on behalf of the HCC-UK/BASL/NCRAS Partnership Steering Group. Primary liver cancer in the UK: Incidence, incidence-based mortality, and survival by subtype, sex, and nation. JHEP Reports 2021;3:1-11
[ 7 ]	S Boonkaya, C Pattarawongpaiboon, P Thaimai, P Ananchuensook, S Sriphoosanaphan, S Tanasanvimon, N Teeyapun, N Pakvisal, N Siripon, S Treeprasertsuk, P Komolmit, K Thanapirom. Efficacy and safety of atezolizuab plus bevacizumab and lenvatinib as first-line systemic therapies for hepatocellular carcinoma : A real-world study. PLOS One. 2025; 20(12) : 1-11
[ 8 ]	F Yuan, C Lenneman, R Krone, GR Williams, D Outlaw Jr, M Katsnelson, S Lirette. Cardiovascular adverse events in patients with hepatocellular carcinoma receiving vascular endothelial growth factor inhibitors. Pharmacotherapy. 2025 ; 44(3) : 214-223
[ 9 ]	H Nagumo, H Nagai, K Higai, T Matsuda, Y Igarashi. Effects of Atezolizumab plus Bevacizumab on skeletal muscle volume and cardiac function in patients with hepatocellular carcinoma. Oncology. 2025; 103 (5): 369-379
[ 10 ]	GK Abou-Alfa, G Lau, M Kudo, S Chan, RK Kelley, J Furuse, W Sukeepaisarnjaroen, Y-K Kang, T Van Dao, EN De Toni, L Rimassa, V Breder, A Vasilyev, A Heurgue, VC Tam, K Mody, SC Thungappa, Y Ostapenko, T Yau, S Azeve do, M Varela, A-L Cheng, S Qin, P Galle, S Ali, M Marcovitz, M Makowsky, P He, JF Kurland, A Negro, B Sangro. Tremelimumab and Durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 2022; 1(8):1-12
[ 11 ]	I Kournoutas, P Marell, J Gile, A Peersen, P Shah, K VanDommelen, SD Kamath, G Gupta, M Akce, J DongYang, P-J Chen, N Naleid, A Mahipal, N Peterson, V Sahai, W Ma, Z Jin, T Halfdanarson, LF Kankeu, LA Washburn, CB Conboy, M Torbenson, A Goenka, S Thompson, SK Venkatesh, P Starlinger, L Roberts, GJ Gores, H Babiker, D Ahn, M Borad, T Bekaii-Saab, A Jatoi, R R McWilliams, F-S Ou, NH Tran. First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocelluar carcinoma: a real world, multicenter retrospective study. The Oncologist 2025; 30 (11): 1-12
[ 12 ]	LA Dawson, K Winter, J Knox, AX Zhu, S Krishnan, C Guha, LA Kachnic, M Gillin, TS Hong, T Craig, et al. NRG / RTOG 1112 : Randomized Phase III study of Sorafenib vs. Stereotactic Body Radiation therapy (SBRT) followed by Sorafenib in Hepatocellular Carcinoma (HCC) (NCT01730937). Int J Radiat Oncol Biol Phys 2022 , 114, 1057
[ 13 ]	H Li, Z Wu, J Chen, K Su, L Guo, K Xu, T Gu, Y Jiang, P Wang, H Zeng, et al. External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma : A systematic review and meta-analysis. Clin Exp Med 2022.
[ 14 ]	S Hayashi, H Tanaka, H Hoshi. External Beam Radiotherapy for painful bone metastases from hepatocellular carcinoma : multiple fractions compared with an 8-Gy single fraction. Nagoya J Med Sci 2014; 76 : 91-99
[ 15 ]	L Ielasi, B Stefanini, F Piscaglia, A Granito, F Tovoli. A case of advanced hepatocellular carcinoma with bone metastases managed with tyrosine kinase inhibitors and aggressive palliative radiation therapy : role of combination therapy for extending survival. Gastroenterology Insights 2023 ; 14 : pp38-44
[ 16 ]	L Cerrito, M Pallozzi, I Urbani, S Archilei, S Miliani, E Creta, L Stella, A Gasbarrini, FR Ponziani. Unexpected Therapeutic Implications : The Abscopal Effect in the Management of Hepatocellular Carcinoma. Cancers 2026; 18 (408)
[ 17 ]	SMN Wong. Comparison of SBRT and SIRT with combination IO for locally-advanced, unresectable HCCs (BIIRTH). ClinicalTrials.gov (accessed in March 2026)
[ 18 ]	ACY Chan, CL Chiang. Downstaging Unresectable Hepatocellular Carcinoma to Resectable disease with combined Immunotherapy and Stereotactic Beamed Radiotherapy : A Pilot Study 2025.ClinicalTrials.gov (accessed in March 2026)